Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytokine-induced killer cells (A.O. Ospedale Papa Giovanni XXIII)
- Development stage
- Unknown
- Lead developer
- Papa Giovanni XXIII Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational adoptive cellular immunotherapy, developed by A.O. Ospedale Papa Giovanni XXIII, utilizes donor-derived cytokine-induced killer (CIK) cells for the treatment of hematologic malignancies relapsing after allogeneic stem cell transplantation. CIK cells are ex vivo expanded and activated T lymphocytes produced by the sequential incubation of peripheral blood mononuclear cells with interferon-gamma (IFN-γ), anti-CD3 monoclonal antibody (OKT3), and interleukin-2 (IL-2). The resulting cell population is primarily composed of CD3+/CD56+ natural killer T cells, which possess both T cell and natural killer (NK) cell properties, enabling MHC-unrestricted cytotoxicity against tumor cells. The therapy is typically evaluated in a sequential regimen following unmanipulated donor lymphocyte infusions (DLI) to enhance the graft-versus-leukemia effect while minimizing the risk of graft-versus-host disease.
- Other names
- CIK cellsdonor-derived cytokine-induced killer cellsin vitro expanded Cytokine Induced Killer cellscytokine-induced killer cells-A.O. Ospedale Papa Giovanni XXIII-hematologic malignancies
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on cytokine-induced killer cells (A.O. Ospedale Papa Giovanni XXIII).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytokine-induced killer cells (A.O. Ospedale Papa Giovanni XXIII).